AME position statement: primary hyperparathyroidism in clinical practice

J Endocrinol Invest. 2012 Jul;35(7 Suppl):2-21.
No abstract available

Publication types

  • Practice Guideline

MeSH terms

  • Bone Density Conservation Agents / therapeutic use
  • Bone Diseases / etiology
  • Calcimimetic Agents / therapeutic use
  • Diphosphonates / therapeutic use
  • Female
  • Humans
  • Hyperparathyroidism, Primary / complications
  • Hyperparathyroidism, Primary / diagnosis*
  • Hyperparathyroidism, Primary / drug therapy
  • Hyperparathyroidism, Primary / surgery
  • Kidney Diseases / etiology
  • Male
  • Parathyroid Hormone / blood
  • Parathyroidectomy
  • Severity of Illness Index

Substances

  • Bone Density Conservation Agents
  • Calcimimetic Agents
  • Diphosphonates
  • Parathyroid Hormone